

Peter H. Khoury, Ph.D., MBA Appointed President and Chief Executive Officer of Nanotherapeutics

Alachua, FL, June 20, 2017 – Nanotherapeutics, Inc., a biologics focused contract development and manufacturing organization (CDMO), today announced that Peter H. Khoury, Ph.D., MBA, formerly Senior Vice President and Chief Commercial Officer, has been appointed President and Chief Executive Officer of the Company.

Commenting on today's announcement, Dr. Khoury stated, "I am honored to accept the roles of President and Chief Executive Officer and look forward to guiding Nanotherapeutics as the Company continues to leverage its proprietary technology platforms and exceptional industry relationships toward its goal of becoming the global leader in advanced biologics manufacturing, with a focus on infectious disease."

Before joining Nanotherapeutics in August 2016, Dr. Khoury spent the prior two years with the Bill & Melinda Gates Foundation, serving as Senior Program Officer, Life Science Partnerships, Office of the President for Global Health. Among his responsibilities, Dr. Khoury spearheaded the expansion of industry engagement with the developing country manufacturer (DCM) industry sector, including relationship management at the "C" level for strategically important and complex DCMs focused on life-saving initiatives including vaccines, biologics, medical diagnostics and generic products.

Prior to the Gates Foundation, from 2002 to 2012, Dr. Khoury was Vice President, Global Marketing at Baxter International, where he led the development and implementation of the company's vaccines business strategies, product management, business plans, and ex-European vaccine sales. While there, Dr. Khoury also led global biosecurity and pandemic influenza sales and marketing, as well as government contracting efforts, solidifying key contracts with the U.S. Government and multiple foreign governments in addition to development programs with the Department of Health and Human Services, National Institutes of Health and National Institute of Allergy and Infectious Diseases.

Before Baxter International, from 1993 to 2002, Dr. Khoury served in numerous positions of increasing responsibility in the marketing and sales organization at Merck & Co., Inc., with his last position as Director, Database and Direct Marketing.

Dr. Khoury earned his Bachelor's degree in Biology and Ph.D. in Microbiology from Syracuse University, and received his Master's in Business Administration in General Management/Marketing from Cornell University's Johnson Graduate School of Management.

About Nanotherapeutics, Inc.

Nanotherapeutics, Inc. is a biologics focused contract development and manufacturing organization (CDMO) serving both government and commercial clients. Capabilities of Nanotherapeutics, Inc. include a pilot facility for performing optimization of upstream, downstream and formulation functions, bulk cGMP manufacturing including Biosafety level-3 (BSL-3), and analytical development for proteins, antibodies, viral vaccines and gene therapy drug products. The Company provides expertise from preclinical through FDA licensure in a variety of production platforms, including microbial and mammalian cell culture and its



proprietary serum protein-free Vero cell platform, a highly versatile platform that has been developed and utilized to deliver a wide range of candidate and licensed vaccines against emerging viral diseases. For more information, visit the Company website at www.nanotherapeutics.com.

CONTACTS:

At Nanotherapeutics, Inc.

Dennis Tomisaka, 386-462-9663

Director, BD Special Projects

dtomisaka@nanotherapeutics.com

or

At Rx Communications Group, LLC

Melody A. Carey, 917-322-2571

President and Chief Executive Officer

mcarey@rxir.com

###